Search IPOs
AVIENCE · NSE · Biotechnology
Avience Biomedicals IPO listed on 25 Jun 2026 on NSE at ₹395.20, a gain of 90.00% over the issue price of ₹208.00. The IPO was subscribed 385.33x overall.
Avience Biomedicals IPO tentative timeline covering IPO opening, closing, basis of allotment, refunds, demat credit, and listing dates.
| Event | Date |
|---|---|
| IPO Open Date | 18 Jun 2026 |
| IPO Close Date | 22 Jun 2026 |
| Basis of Allotment | 23 Jun 2026 |
| Initiation of Refunds | 24 Jun 2026 |
| Credit of Shares to Demat | 24 Jun 2026 |
| Listing Date | 25 Jun 2026 |
Listing day gain
+90%
Listed at ₹395.2 (issue ₹208)
Issue
₹208
Listing
₹395.2
Current
₹414.95
+99.5% vs issue
Day range
₹395.2 – ₹414.95
Issue Size
1,453,800 shares
(aggregating up to ₹30.00 Cr)
Issue Price
₹196 – ₹208
Face Value
₹10/share
Market Lot
600 shares
Retail Min Investment
₹249,600
Listing At
NSE
Sale Type
fresh issue
Fresh Issue
1,371,600 shares
(aggregating up to ₹28 Cr)
Offer for Sale
[.]
Reserved for Market Maker
82,200 shares
(aggregating up to ₹2.00 Cr)
Issue Type
book building
Open Date
18 Jun
Close Date
22 Jun
Allotment
23 Jun
Listing
25 Jun
Last updated: 3 months ago
| Date | IPO Issue Price (₹) | GMP (₹) | Est. Listing Price (₹) | Est. Profit Amount (₹) | Est. Profit % | Last Updated |
|---|---|---|---|---|---|---|
| 25 Jun 2026 Latest | ₹208 | ₹145 | ₹353 | ₹145 |
69.71%
|
12:11 PM |
| 24 Jun 2026 | ₹208 | ₹145 | ₹353 | ₹145 |
69.71%
|
9:01 PM |
Showing the 2 most recent GMP entries.
View full GMP historyLatest snapshot: 22 Jun 2026
| Category | Subscribed (x) | No. of Applications |
|---|---|---|
| QIB | 196.77x | 172 |
| NII | 597.62x | 31,835 |
| bNII (bids above ₹10L) | 670.77x | 16,492 |
| sNII (bids below ₹10L) | 451.32x | 15,343 |
| Individual Investors | 401.21x | 160,887 |
| Total | 385.33x | 224,729 |
Showing the latest subscription snapshot.
View full subscription historyMr. Dharam Deo Choudhary, Mr. Ram Nagina Choudhary, Mr. Janardan Pal and Ms. Deepa Choudhary.
New to lot sizes and investment limits? Read our guide on IPO lot size and minimum investment.
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 2 | 1,200 | ₹249,600 |
| Retail (Max) | 2 | 1,200 | ₹249,600 |
| S-HNI (Min) | 3 | 1,800 | ₹374,400 |
| S-HNI (Max) | 8 | 4,800 | ₹998,400 |
| B-HNI (Min) | 9 | 5,400 | ₹1,123,200 |
Want to understand how IPO shares are divided between investor categories? Read our guide on IPO reservation structure.
| Category | Shares Offered |
|---|---|
| QIB Shares Offered | 273,600 (47.01%) |
|
•
QIB (Ex. Anchor) Shares Offered
|
273,600 (47.01%) |
| NII (HNI) Shares Offered | 207,000 (14.24%) |
|
•
bNII > ₹10L
|
138,000 (9.49%) |
|
•
sNII < ₹10L
|
69,000 (4.75%) |
| Individual Investors Shares Offered | 481,200 (33.10%) |
| Market Maker Shares Offered | 82,200 (5.65%) |
| Total Shares Offered | 1,044,000 (100.00%) |
Founded in 2019, Avience Biomedicals Limited has rapidly emerged as a trusted name in India’s healthcare ecosystem, specializing in life-saving molecular diagnostics and medical equipment. Operating from its state of the art manufacturing facility in Noida, the company bridges the gap between complex biotechnology and everyday medical needs.
Avience focuses on a diverse B2B and B2G portfolio, including in-vitro diagnostic (IVD) rapid test kits, advanced hematology analyzers, and biochemistry equipment. Beyond manufacturing its own high-quality diagnostic solutions, the company serves as a vital distribution partner for cutting-edge international medical technologies, introducing global standards to the domestic market.
What truly sets Avience apart is its commitment to accessibility. The internal research and development team constantly hunts for new molecular markers, aiming to make advanced, predictive healthcare affordabl especially for underserved rural communities. By pairing strict quality control with an aggressive growth strategy, Avience balances corporate success with genuine social impact, ensuring that reliable testing reaches the people who need it most.
Standalone · ₹ in Crores
| Particulars | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Total Revenue | 10.93 | 16.64 | 29.54 |
| Profit After Tax (PAT) | 0.78 | 1.99 | 5.19 |
| EBITDA | 1.43 | 3.15 | 7.65 |
| Total Assets | 10.02 | 25.63 | 43.6 |
| Net Worth | 4.08 | 6.07 | 20.6 |
| Reserves & Surplus | 0.79 | 2.79 | 16.57 |
| Total Borrowing | 2.66 | 7.73 | 13.75 |
Revenue & Profit Trend
The basis of allotment for Avience Biomedicals IPO was finalised on 23 Jun 2026. You can check your allotment status using your PAN number or application number on the Skyline Financial Services Pvt.Ltd. portal or BSE.
The Avience Biomedicals IPO is expected to open in Jun 2026, subject to SEBI approval. Final dates will be updated once announced officially.
The price band for Avience Biomedicals IPO is ₹196.00 - ₹208.00 per share.
As per market sources, Avience Biomedicals IPO GMP is currently ₹145.00. GMP is tracked daily in the grey market. GMP indicates unofficial demand but does not guarantee listing gains.
The subscription status for Avience Biomedicals IPO stands at 385.33x overall.
The listing date for Avience Biomedicals IPO is 25 Jun 2026.
No comments yet. Be the first to comment!
